The clinical performance is complex and often involves multi-systematic stress. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Individualised development of treatment programs for treatment and management of sub-neurons, typically includes drug therapy, rehabilitation intervention, and regular follow-up to multiple-dimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved.
Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of sub-neural tumours. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of blood tumours, who provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.